Segall Bryant & Hamill LLC Has $6.11 Million Stock Position in Bath & Body Works, Inc. $BBWI

Segall Bryant & Hamill LLC lifted its position in Bath & Body Works, Inc. (NYSE:BBWI) by 17.7% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 327,089 shares of the company’s stock after buying an additional 49,100 shares during the period. Segall Bryant & Hamill LLC’s holdings in Bath & Body Works were worth $6,107,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Royal Bank of Canada increased its holdings in shares of Bath & Body Works by 92.8% in the first quarter. Royal Bank of Canada now owns 59,877 shares of the company’s stock worth $1,815,000 after acquiring an additional 28,815 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Bath & Body Works by 15.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 645,970 shares of the company’s stock valued at $19,586,000 after purchasing an additional 87,529 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Bath & Body Works by 7.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 562,757 shares of the company’s stock valued at $17,063,000 after purchasing an additional 36,684 shares during the period. Intech Investment Management LLC acquired a new position in shares of Bath & Body Works in the 1st quarter valued at approximately $1,155,000. Finally, Geneos Wealth Management Inc. increased its stake in Bath & Body Works by 217.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 1,169 shares of the company’s stock worth $35,000 after purchasing an additional 801 shares in the last quarter. Institutional investors and hedge funds own 95.14% of the company’s stock.

Bath & Body Works Stock Performance

NYSE BBWI opened at $21.00 on Tuesday. The stock has a market capitalization of $4.23 billion, a price-to-earnings ratio of 5.90, a PEG ratio of 1.99 and a beta of 1.38. The stock’s 50 day moving average price is $20.21 and its two-hundred day moving average price is $20.34. Bath & Body Works, Inc. has a 52 week low of $14.27 and a 52 week high of $32.32.

Bath & Body Works (NYSE:BBWI) last issued its quarterly earnings results on Wednesday, May 27th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.03. The company had revenue of $1.38 billion during the quarter, compared to analysts’ expectations of $1.36 billion. Bath & Body Works had a net margin of 10.03% and a negative return on equity of 45.34%. The business’s quarterly revenue was down 3.2% on a year-over-year basis. During the same period last year, the business earned $0.49 EPS. Bath & Body Works has set its Q2 2026 guidance at 0.300-0.300 EPS and its FY 2026 guidance at 2.400-2.650 EPS. On average, equities research analysts forecast that Bath & Body Works, Inc. will post 2.63 EPS for the current year.

Bath & Body Works Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 19th. Investors of record on Friday, June 5th were issued a dividend of $0.20 per share. The ex-dividend date was Friday, June 5th. This represents a $0.80 annualized dividend and a yield of 3.8%. Bath & Body Works’s dividend payout ratio is presently 22.47%.

Analyst Ratings Changes

Several analysts have commented on BBWI shares. Piper Sandler began coverage on shares of Bath & Body Works in a report on Friday, May 15th. They set a “neutral” rating and a $20.00 target price on the stock. Telsey Advisory Group reduced their price target on shares of Bath & Body Works from $25.00 to $22.00 and set a “market perform” rating for the company in a report on Thursday, May 28th. Wells Fargo & Company increased their price objective on shares of Bath & Body Works from $25.00 to $26.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 23rd. Weiss Ratings upgraded shares of Bath & Body Works from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 9th. Finally, TD Cowen boosted their price objective on shares of Bath & Body Works from $20.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, May 28th. Three analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $21.93.

Bath & Body Works Profile

Bath & Body Works, Inc is a leading specialty retailer focused on personal care, home fragrance and complementary products. Through its flagship Bath & Body Works brand, the company offers a diverse assortment of shower gels, lotions, fragrance mists, candles and home fragrance items. Its product portfolio also includes the White Barn Candle Co range of premium scented candles and diffusers. Bath & Body Works serves consumers through a combination of brick-and-mortar stores and e-commerce platforms, delivering seasonal collections, limited-edition releases and signature scent lines.

Founded in 1990 as part of Limited Brands (now L Brands), Bath & Body Works opened its first store in New Albany, Ohio, and quickly expanded across the United States.